Clinical Trial Search

Primary: Number of Participants With Adverse Events of Special Interest (AESI) Using Initial Exposure Intent-to-Treat (ITT) Strategy — 48; 29; 44; 24 Participants

Primary: Post-operative Evidence of Adenomyoma Tissue Ablation Effect by Area (n) as Assessed by Pathological Analysis — 9; 8; 7; 6 treated areas

Primary: Pre-treatment OSCC Morphology and PDPN Expression — 2.8; 3.4; 2.5 score on a scale from 1 to 5 — p=<0.05

Primary: Cholesterol Efflux Capacity (CEC) — 1.30; 0.65 Ratio

Primary: Change (From Intake to Post-therapy) in Resting-state Functional Connectivity Between Posterior Cingulate Cortex (PCC) and Dorsolateral Prefrontal Cortex (dlPFC)…

Primary: Percentage of Glycated Hemoglobin Among Participants at Baseline and 18-week Follow-up — 8.0; 7.40; 8.40; 7.35 Percentage of glycated hemoglobin — p=0.900

Primary: Glutamate in the Dorsal Anterior Cingulate Cortex — 8.11; 7.05 Institutional Units — p=0.027

Primary: Intentions to Adhere to Colorectal Cancer Screening (CRCS) Recommendations — 18; 16; 21; 19 Participants

Primary: Calgary Depression Rating Scale (CDRS) — 18.20; 17.15; 16.09; 15.39 score on a scale

Primary: Revised Memory and Behavior Problems Checklist, Reactivity Subscale — 40.7; 35.6; 35.7; 35.0 score on a scale

Primary: Stuttered Syllables in Passage Reading (Change in the Percentage of Stuttered Syllables After 5 Days of Intervention From Baseline) — -1.41; -0.81 percentage of…

Primary: Change in Mean Completion Time for Timed Test — -2.8; -7.5 Minutes

Primary: Pain Levels Using the Visual Analog Scale — 2.5; 4.06 score on a scale (0-10 on VAS pain scale — p=<0.001

Primary: Change From Baseline to the Average of the Entire Treatment Period Reported, in the Average Pre-dose Morning Peak Expiratory Flow (PEF) — 16.45; -3.63 L/min — p=<0.001

Primary: Duration of Response — 8.1 months